Business
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects-- Positive
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects-- Positive interim dose optimization data from proof-of-concept Phase 1b study, reported in second quarter 2020 Additional second quarter and recent highlights from Phase 1b proof-of-concept study include:-- Completed enrollment in dose optimization expansion cohort-- Initiated enrollment in schedule optimization part of the study Final dose optimization data and preliminary schedule optimization data anticipated in fourth quarter 2020 Received $10.3 million in aggregate net proceeds in June 2020 from public offering of common stock WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.\n “We continue to make important progress advancing our goal to deliver a novel chemoprotective medicine that can protect cancer patients against multiple serious, often life-threatening chemotherapy-induced side effects,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer of Aileron. “We’re pleased with the preliminary data we reported in June from the dose optimization part of our ongoing Phase 1b proof-of-concept clinical trial of ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in small cell lung cancer patients undergoing treatment with topotecan. These data showed clinically meaningful protection against severe chemotherapy-induced anemia and thrombocytopenia. In addition, a signal of protection against Grade 4 neutropenia in the first treatment cycle was observed at the 0.3 mg/kg dose level.” Dr. Aivado further commented, “Key inflection points for Aileron in the coming months include final Phase 1b dose optimization data in addition to preliminary data from the recently initiated schedule optimization part of the trial, both in the fourth quarter, as well as the initiation of our healthy volunteer study of ALRN-6924 in the third quarter. These milestones will further support and de-risk our plans to expand development of ALRN-6924 for multiple cancer types and various chemotherapies, to ultimately deliver this unique chemoprotective medicine to as many patients with p53-mutated cancers as possible, which could translate ...